Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
نویسندگان
چکیده
منابع مشابه
The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth fact...
متن کاملCombinations of targeted therapies in human cancers
human cancers are driven by one specific molecular event, such as, for example, chronic myeloid leukemia. Human cancers appear to be generally derived from multiple oncogenic alterations maturing through their own particular mechanisms [1]. One major consequence of such alterations is the dysregulation of intracellular signaling pathways favoring tumor cell survival, proliferation, and motility...
متن کاملMolecularly targeted therapies in head and neck cancers.
Head and neck cancers (HNC) are 6th most common malignancies according to the incidence rate. Over 85% of tumors of this region are epithelial tumors, especially squamous cell carcinomas (head and neck squamous cell carcinomas - HNSCC). Surgery, chemotherapy and radiotherapy are still the standard for the treatment of HNC. Despite the great development of the various methods of treatment, survi...
متن کاملTargeted therapies in the treatment of colorectal cancers.
BACKGROUND In solid organ malignancies, no tumor type has seen a greater impact from the development of novel targeted therapies in 2004 than metastatic colorectal cancer. METHODS We review the current progress to date with the use of monoclonal antibodies in colorectal cancer and look at newer therapies under investigation. RESULTS Two monoclonal antibodies received Food and Drug Administr...
متن کاملChemoresistance and targeted therapies in ovarian and endometrial cancers
Gynecological cancers are known for being very aggressive at their advanced stages. Indeed, the survival rate of both ovarian and endometrial cancers is very low when diagnosed lately and the success rate of current chemotherapy regimens is not very efficient. One of the main reasons for this low success rate is the acquired chemoresistance of these cancers during their progression. The mechani...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancers
سال: 2021
ISSN: 2072-6694
DOI: 10.3390/cancers13030458